Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.67 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.46 |
| ▸ | CCKAR | P32238 | 3/20 | 0.43 |
| ▸ | CCKBR | P32239 | 3/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18697474 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL16182631 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL12806533 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24284196 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL12287742 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24198476 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL23051891 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24899310 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL20911267 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL19243816 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2910571-B1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | disclosed |
| WO-2010060667-A1 | PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES | NOVO NORDISK A/S (DK) | 2010-06-03 | — | — | WO | disclosed |